Activist investor Kfir Silberman, through L.I.A. Pure Capital, disclosed a 12.61% stake in Evogene Ltd (NASDAQ:EVGN) and demanded a special meeting to overhaul the board as the company simultaneously forges an AI-powered drug discovery partnership with Tel Aviv University to integrate ChemPass into a Design-Make-Test-Analyze workflow.
Previous Week Recap
- Activist Seeks Board Shake-Up: Kfir Silberman, via L.I.A. Pure Capital, disclosed a 12.61% stake in Evogene Ltd (EVGN) and requested a special meeting to replace most directors and seat his board nominees.
- AI-Driven Molecule Discovery Collaboration: Evogene (EVGN) partners with Tel Aviv University BCDD to integrate ChemPass AI with TAU labs, creating a Design-Make-Test-Analyze workflow for AI-driven small‑molecule discovery and validation.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.